About Molecular Cancer Therapeutics

Scope

Molecular Cancer Therapeutics publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology. To reflect the evolving field of therapeutics, the journal’s interest extends to all selective drugs including small molecule inhibitors, antibody-drug conjugates, antibody cytokine fusions, bispecific antibodies, cell therapies, gene therapies, radio-immunotherapeutics, vaccines, viral therapies, and other experimental approaches in oncology.

Specific areas of interest are the disclosure of translational investigations of novel drug therapies, preclinical studies of approved therapeutics (including their combination with radiation therapy), mechanisms of action, mitigation of resistance, biomarkers of response, novel models and technology, and applications of big data in drug discovery.

The following guidelines, which may be revised from time to time, describe what the Editors are looking for in submitted manuscripts:

Data/experiments are substantive and support conclusions; all key experiments are designed and performed properly.
Sufficient detail is provided to facilitate repetition of the experiments to verify data.
Rigorous statistical evaluation is performed. Sufficient group size is used for animal studies.
Appropriate replicates in cellular studies are used.
Relevant cell lines, animal models, and assays are utilized.
Studies must be performed according to AACR and Institutional Guidelines.
Multiple relevant cell lines (or patient specimens) are examined/used/studied to support conclusions.
Studies are performed using relevant concentrations of agents, conditions, schedules, and other related material. Where human data exists, the data should be used to define parameters for laboratory studies.
Appropriate controls are employed for all experiments (especially inactive analog compounds).
In vivo studies should go beyond establishment of biological effect and show modulation of the intended target (or cellular pathway) in vivo. Pharmacokinetic (PK)/pharmacodynamics (PD) studies are extremely useful; dose-response should be demonstrated.
Inclusion of relevant structures of compounds mentioned or used in the work is essential and enhances the readability of the paper. Studies with uncharacterized mixture of Natural Products will not be considered.
For novel structures previously unreported, experimental details of synthesis should be included in the main body of the paper or in Supplementary Material.
Any references or patents cited that provide the synthesis of compounds should be specific, not general, and should be easily obtained.

Manuscript Submission

Molecular Cancer Therapeutics welcomes submissions of primary research, reviews and letters to the editor. For descriptions and length requirements of the article types available to submitting authors, see the journal’s Categories of Articles.

The AACR Journals all use a similar Editorial Process and adhere to the same overarching Editorial Policies, both of which are detailed in the Instructions for Authors. These instructions contain important guidelines on authorship, publishing ethics, availability of materials and data, and data analysis and reporting. Authors should be familiar with these instructions prior to submitting their work to the journal.

Manuscripts are stringently reviewed for high standards of scientific merit, and only those that report results of novel, timely, and broadly-significant research are accepted for publication. Please note that Molecular Cancer Therapeutics does not consider appeals.

Submit your article to Molecular Cancer Therapeutics

Journal Metrics

For detailed metrics about Molecular Cancer Therapeutics and the other AACR journals see AACR Journals Metrics.

Editors and Editorial Board

Editorial oversight of Molecular Cancer Therapeutics and decisions on manuscripts submitted to the journal are the responsibility of the Editorial Board with support from journal staff. See Editorial Board for more information.

Copyright, Permissions and Access

Material published in Molecular Cancer Therapeutics is covered and protected by copyright. An author can either formally transfer copyright to the AACR, and be granted considerable reuse rights, or can publish an article as open access under a Creative Commons license. The final typeset version of every published article is rendered freely accessible 12 months after publication. In addition, the AACR assists authors in satisfying major funder Open Access archiving mandates by depositing the accepted author version of their article in a designated public repository. For additional details about all these topics, see Copyright, Permissions and Access.

Publication Fees

To defray publication costs and to support other AACR programs, publication in Molecular Cancer Therapeutics involves the payment of a base publication fee and an additional fee for each display item. If no financial support exists, authors may apply for a waiver of the fixed publication fee at the time of submission. See Publication Fees for further details.

Journal Information

Molecular Cancer Therapeutics (MCT) (Print ISSN: 1535-7163; Online ISSN 1538-8514) is published monthly, one volume/year, by the American Association for Cancer Research, Inc. (AACR).

Molecular Cancer Therapeutics is abstracted and/or indexed in BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.

Back Issues and Single Copy Sales

Subject to availability, single or back issues of Clinical Research may be purchased for $60 per copy in the U.S. or $65 per copy outside the U.S. For more information, contact:

AACR Publications Sales & Marketing Department
American Association for Cancer Research
615 Chestnut Street, 17th Floor
Philadelphia, PA 19106-4404
Toll Free: (855) 744-4667 or (215) 440-9300
E-mail: pubsales@aacr.org

Contact